

## Synthesis and Studies of Antibacterial Agents

C.P. SINGH\*, S.S. NAYAL and S.M. CHAUHAN

Chemistry Department





Sahu Jain College, Najibabad-246 763, India

A new series of heterocyclic compounds namely N<sup>1</sup>-(2-fluorobenzoyl)-5,5'-dimethyl cyclohexane 4-(sulpha/substituted phenyl azo)-1,2-diazoles have been synthesised and screened for their biological activity.

### INTRODUCTION

Heterocyclic compounds specially diazole derivatives possess varied biological activity and have found application as potential pharmaceutical agents, such as potential anti-inflammatory<sup>1,2</sup>, tranquillizing, muscle relaxant, hypnotic, anticonvulsant<sup>3-7</sup>, antituberculous<sup>8</sup>, antineoplastic<sup>9</sup>, antidiabetic<sup>10</sup>, antifertility<sup>11</sup>, antiepileptic<sup>12</sup>, proteolytic<sup>13</sup>, antiobesity, anticholinergic<sup>14</sup> antitumour<sup>15, 16</sup> activity.

In view of the importance of sulpha/substituted hydrazono derivatives of 5,5'-dimethyl cyclohexane-1,3-diones<sup>17</sup> as precursors for the synthesis of potential biological active diazole derivatives. It was thought worthwhile to synthesise different sulpha/substituted hydrazono derivatives of 5,5'-dimethyl cyclohexane-1,3-diones, and their cyclised products with 2-fluorobenzoyl acid hydrazides with the hope that it would show promising biological activity.



### EXPERIMENTAL

All the chemicals used are either BDH or E. Merck and AR grade.

### Synthesis of Bicyclic-N<sup>1</sup>-(2-Fluorobenzoyl)-5,5'-Dimethyl Cyclohexane-4-(x) Azo-1,2-Diazoles

A mixture of sulpha/substituted hydrazono 5,5'-dimethyl cyclohexane-1-3-diones (0.05 moles) and 2-fluoro benzoic acid hydrazides (0.05 mole) was refluxed in glacial acetic acid (30 mL) for 4 h and the contents were left overnight. The coloured solid mass was filtered, washed with water, dried and crystallized from glacial acetic acid to furnish shining coloured crystals of N<sup>1</sup>-(2-fluorobenzoyl)-5,5'-dimethyl cyclohexane-4-(x) azo-1,2-diazoles.

Their characteristics are recorded in Table-1. The yields vary from 75 to 85%.

TABLE-1  
CHARACTERISTICS OF N<sup>1</sup>-(2-FLOURO BENZOYL)-5,5'-DIMETHYL CYCLOHEXANE-4-(X) AZO-1,2-DIAZOLES

S.No.	Substituted Groups (X) (Colour)	m.p. (°C)	Molecular formula	N %, Found (Calcd.)	R <sub>f</sub> Value
1.	2-Chloro phenyl (Pale yellow)	163	C <sub>21</sub> H <sub>18</sub> N <sub>4</sub> OCIF	14.01 (14.12)	0.7194
2.	4-Nitro phenyl (Yellow)	175	C <sub>21</sub> H <sub>18</sub> N <sub>5</sub> O <sub>3</sub> F	16.89 (17.19)	0.8391
3.	4-Methyl phenyl (Dark yellow)	183	C <sub>22</sub> H <sub>21</sub> N <sub>4</sub> OF	18.14 (18.49)	0.8333
4.	4-Bromo phenyl (Orange)	162	C <sub>21</sub> H <sub>18</sub> N <sub>4</sub> OBrF	12.35 (12.69)	0.6106
5.	2,4,6,-Tribromo phenyl (Light yellow)	179	C <sub>21</sub> H <sub>16</sub> N <sub>4</sub> OBr <sub>3</sub> F	9.12 (9.35)	0.7251
6.	2,3-Dimethyl-1-Phenyl pyrazolone (Shinning brown)	180	C <sub>26</sub> H <sub>25</sub> N <sub>6</sub> O <sub>2</sub> F	17.52 (17.79)	0.7338
7.	2-Sulphonamidobenzene (Pale yellow)	153	C <sub>21</sub> H <sub>20</sub> N <sub>5</sub> O <sub>3</sub> SF	15.43 (15.87)	0.7045
8.	N <sup>1</sup> -2-Acetyl Sulphonamido benzene (Pale yellow)	189	C <sub>23</sub> H <sub>22</sub> N <sub>5</sub> O <sub>4</sub> SF	13.99 (14.49)	0.8531
9.	N <sup>1</sup> -2-Thiazolyl sulphonamido benzene (Shining yellow)	171	C <sub>24</sub> H <sub>21</sub> N <sub>6</sub> O <sub>3</sub> SF	16.82 (17.07)	0.7935
10.	N <sup>1</sup> -2-Guanyl sulphonamido benzene (Orange)	165	C <sub>22</sub> H <sub>22</sub> N <sub>7</sub> O <sub>3</sub> SF	20.17 (20.28)	0.8521
11.	N <sup>1</sup> -2-(4,6-Dimethyl) pyrimidyl sulphonamido benzene (Yellow)	193	C <sub>27</sub> H <sub>26</sub> N <sub>7</sub> O <sub>3</sub> SF	16.94 (17.91)	0.6818

\*The R<sub>f</sub> values for all the compounds: on silica Gel plates (thickness 0.5 mm.), developing solvent acetone/DMF (3 : 1), on saturated chambers at room temperature (20 ± 1°C)

The homogeneity and purity of the compounds were checked through TLC and structure were established by elemental analysis, IR, NMR spectroscopic studies. R<sub>f</sub> values are determined using acetone/DMF solvents.

IR spectra in KBr were recorded on a Perkin-Elmer grating IR spectro-

photometer. The spectra had characteristic peaks at  $750\text{ cm}^{-1}$   $\nu(\text{C—Cl})$ ,  $1120\text{ cm}^{-1}$   $\nu(\text{C—F})$ ,  $1220\text{ cm}^{-1}$   $\nu(\text{—C}(\text{CH}_3)_2)$ ,  $2950\text{ cm}^{-1}$   $\nu(\text{—CH}_2)$ ,  $1680\text{ cm}^{-1}$   $\nu(\text{C}=\text{N})$ ,  $1440\text{ cm}^{-1}$   $\nu(\text{C—N})$ ,  $1670\text{ cm}^{-1}$   $\nu(>\text{C}=\text{O})$  which help in establishing the structure.

The structures of substituted bicyclic hetero compounds were also confirmed by  $^1\text{H-NMR}$  spectral studies. NMR ( $\text{CDCl}_3$ ): ( $\delta$ ) 2.21 (2S, 6,  $\text{C}_1$   $\left\langle \begin{array}{l} \text{CH}_3 \\ \text{CH}_3 \end{array} \right.$ ), 3.12 (S, 4,  $\text{—CH}_2$ ), 4.25 (dd, 4, ArH-F, *ortho* to X,  $J = 20$  and 2 Hz), 7.43 (bS, 4, ArH,  $\text{C}_1\text{—Cl}$ ).

TABLE-2  
NAME OF THE COMPOUNDS (DILUTION 1000 PPM)

S. No.	Name of bacteria	$\text{N}^1$ -(2-Fluoro benzoyl) 5,5'-dimethyl cyclohexane-4- $\text{N}^1$ -2-acetyl sulphonamido benzene azo-1,2-diazole	$\text{N}^1$ -(2-Fluoro benzoyl) 5,5'-dimethyl cyclohexane-4- $\text{N}^1$ -2-sulphonamido benzene azo-1,2-diazole	$\text{N}^1$ -(2-Fluoro benzoyl) 5,5'-dimethyl cyclohexane-4- $\text{N}^1$ -2-guanyl sulphonamido benzene azo-1,2-diazole	$\text{N}^1$ -(2-Fluoro benzoyl) 5,5'-dimethyl cyclohexane-4- $\text{N}^1$ -2-thiazolyl sulphonamido benzene azo-1,2-diazole	$\text{N}^1$ -(2-Fluoro benzoyl) 5,5'-dimethyl cyclohexane-4- $\text{N}^1$ -2-(4,6-dimethyl) pyrimidyl sulphonamido benzene azo-1,2-diazoles
1.	<i>Bacillus subtilis</i>	+	++	-	++	-
2.	<i>Clostridium sporogenes</i>	-	+++	-	-	+
3.	<i>Micrococcus luteus</i>	++	-	+	-	-
4.	<i>Staphylococcus epidermis</i>	+	-	++	++	++
5.	<i>Staphylococcus aureus</i>	-	++	-	+	+

- = inhibition, + = zone size 2.0 to 4.0 mm, ++ = zone size 4.0 to 6.0 mm, +++ = zone size greater than 6.0 mm.

### Biological Activity

The newly synthesised compounds were screened against pathogenic organism such as *Bacillus subtilis* (ATCC 6633), *Clostridium sporogenes* (ATCC 11437), *Micrococcus luteus* (ATCC 9341), *Staphylococcus epidermis* (ATCC 12228), *Staphylococcus aureus* (NCTT 7447) (ATCC = American type culture collection, NTCC = National type culture collection).

The microbiological reagents used in the present studies are:

- (1) Acetonitrile, and
- (2) Buffer Solution: dipotassium hydrogen phosphate 16.73 g + potassium

dihydrogen phosphate 0.593 g, dissolve in 1000 mL (sterile) water for inj. IP and adjust pH to 8.0 with 18 N phosphoric acid or 10 N potassium hydroxide.

(3) Nutrient-agar media IP Hi-Media Labs. (Pvt) Ltd.):

<i>Composition</i>	<i>g/L</i>
Beef extract	10.00
Peptone	10.00
Sodium chloride	5.00
Agar	12.00

Suspend 37.00 g in 1000 mL distilled water, boil to dissolve the medium completely sterilized by autoclaving at 15 lbs pressure (121°C) for 15 min, apply further procedure as per IP cylinder plate/cup plate method. The compounds namely, N<sup>1</sup>-(2-fluorobenzoyl)-5,5-dimethyl cyclohexane-4-(2-sulphonamidobenzene, N<sup>1</sup>-2-guanyl sulphonamidobenzene, N<sup>1</sup>-2-thiazolyl sulphonamidobenzene, N<sup>1</sup>-2-(4,6-dimethyl) pyrimidyl sulphonamidobenzene, N<sup>1</sup>-2-(acetyl sulphonamidobenzene) azo-1,2-diazoles showed significant activity. Their results are recorded in Table-2.

## REFERENCES

1. K. Kato, M. Hori, O. Ohatani, K. Izumi, T. Kitumikado, H. Asai and S. Sugiura, *J. Med. Chem.*, **20**, 80 (1977).
2. S. Sugiura, K. Kato, O. Ohtani and T. Wakayama, *J. Pharm. Soc.*, **97**, 719 (1977).
3. L.G. Polevoi, Tr., *Nuachn. Konf. Aspir*, i Ord. 1-yi (Pervyi), Mosk. Med. Inst., Moscow, 159, (1964); *Chem. Abstr.*, **65**, 19147 (1966).
4. V.M. Arakumov and Y.M. Batulin, *Farmakol. Toksikol.*, **31**, 402 (1968); *Chem. Abstr.*, **69**, 75439 (1938).
5. L.C. Polevoi, A.N. Kudrin, I.I. Grandberg and A.N. Kost, *Izv. Timiryazev, Sel' Skokhoz Akad.*, 192 (1968); *Chem. Abstr.*, **69**, 1557 (1968).
6. Y.M. Batulin, *Farmakol. Toksikol.*, **31**, 533 (1968); *Chem. Abstr.*, **70**, 2236 (1969).
7. S.S. Parmar, B.R. Pandey, C. Dwivedi and R.D. Haroison, *J. Pharm. Sci.*, **63**, 1152 (1974).
8. R. Behnisch, F. Mietzch and H. Schmidt, *Am. Rev. Tuberc.*, **61**, 1 (1950).
9. H.G. Garg and R.A. Sharma, *J. Pharm. Sci.*, **59**, 350 (1970).
10. H.G. Garg and P.P. Singh, *J. Med. Chem.*, **13**, 1250 (1970).
11. S.S. Tiwari and A. Sharma, *J. Indian Chem. Soc.*, **52**, 153 (1975).
12. G.L. Jenkins, W.H. Hartung and J.B. Data, *The Chemistry of Organic Medicinal Products* (1957).
13. K. Morihara, *J. Biochem.*, **62**, 250 (1967); *Chem. Abstr.*, **67**, 87939t (1967).
14. K.C. Joshi, V.N. Pathak and V. Grover, *Pharmaize*, **34**, 68 (1979).
15. W. Wilson and N. Bottigliere, *Cancer Chemotherapy*, **21**, 137 (1962).
16. C.W. Noell and C.C. Cheng, *J. Med. Chem.*, **12**, 545 (1969).
17. A.C. Ojha and Renu Jain, *The Philippine Journal of Science*, **110**, 91 (1981).